The major aim of WP5 is to establish surrogate serum protein profiles for tumour stroma, in order to predict patients’ response to treatment. To this end, surrogate serum cytokine profiles will be established in serum from clinical pancreatic cancer cases recruited in Europe’s largest pancreatic cancer clinical trials (ESPAC and Telovac). An equivalent study will be performed using serum from the mouse models provided in WP3. Relationships between survival, observed stromal level, protein profiles and treatment groups will elucidate the role of stroma in chemotherapy response.

WP lead:

The University of Liverpool, United Kingdom (ULIV) per Participant

WP members:

Philipps-Universität Marburg, Germany (UNIMAR)
University of Verona, Italy (UNIVR)
Ernst-Moritz-Arndt-Universität Greifswald, Germany (EMAU-G)
Technische Universität München, Klinikum rechts der Isar, Germany (TUM-MED)
Cancer Research UK, United Kingdom (CR-UK)
Lab21 Ltd., United Kingdom (Lab21)

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.